PROCRIT Extended Dosing For Maintenance of Hemoglobin in Pre-Dialysis CKD Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

430

Participants

Timeline

Start Date

July 31, 2007

Primary Completion Date

March 31, 2009

Study Completion Date

March 31, 2009

Conditions
AnemiaRenal Diseases
Interventions
DRUG

epoetin alfa

Continue pre-study once weekly dose of epoetin alfa for 36 weeks

DRUG

epoetin alfa

Double the pre-study once weekly dose of epoetin alfa every 2 weeks for 36 wks

DRUG

epoetin alfa

Quadruple the pre-study once weekly dose of epoetin alfa every 4 weeks for 36 wk

Trial Locations (66)

Unknown

Chula Vista

Fountain Valley

Los Angeles

Lynwood

Orange

Riverside

San Dimas

West Hills

Yuba City

Lakewood

Thornton

Washington D.C.

Clearwater

Miami

Pembroke Pines

Plantation

Springhill

Tampa

West Palm Beach

Zephyrhills

Atlanta

Augusta

Macon

Chicago

Evergreen Park

Peoria

Shreveport

Baltimore

Boston

Methuen

Plymouth

Springfield

Detroit

Flint

Picayune

St Louis

Great Neck

New York

Springfield Gardens

Charlotte

Greenville

Monroe

Dayton

Maumee

Allentown

Doylestown

Erie

Lancaster

Philadelphia

Wynnewood

Providence

Bamberg

Columbia

Orangeburg

Rock Hill

Sumter

Arlington

Fountain Valley

Houston

Longview

San Antonio

Fairfax

Hampton

Petersburg

Richmond

Tacoma

All Listed Sponsors
lead

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

INDUSTRY

NCT00440466 - PROCRIT Extended Dosing For Maintenance of Hemoglobin in Pre-Dialysis CKD Patients | Biotech Hunter | Biotech Hunter